Coherus Oncology (CHRS) Capital Expenditures (2016 - 2025)
Historic Capital Expenditures for Coherus Oncology (CHRS) over the last 13 years, with Q2 2025 value amounting to -$483.4 million.
- Coherus Oncology's Capital Expenditures fell 110850.0% to -$483.4 million in Q2 2025 from the same period last year, while for Sep 2025 it was -$478.7 million, marking a year-over-year decrease of 11014.23%. This contributed to the annual value of $286000.0 for FY2023, which is 8597.35% down from last year.
- According to the latest figures from Q2 2025, Coherus Oncology's Capital Expenditures is -$483.4 million, which was down 110850.0% from $4.7 million recorded in Q1 2025.
- In the past 5 years, Coherus Oncology's Capital Expenditures ranged from a high of $4.7 million in Q1 2025 and a low of -$483.4 million during Q2 2025
- Over the past 5 years, Coherus Oncology's median Capital Expenditures value was $152000.0 (recorded in 2023), while the average stood at -$46.9 million.
- As far as peak fluctuations go, Coherus Oncology's Capital Expenditures soared by 32413.79% in 2022, and later plummeted by 12366776.32% in 2024.
- Quarter analysis of 5 years shows Coherus Oncology's Capital Expenditures stood at $468000.0 in 2021, then crashed by 81.41% to $87000.0 in 2022, then plummeted by 60.92% to $34000.0 in 2023, then plummeted by 117747.06% to -$40.0 million in 2024, then tumbled by 1108.5% to -$483.4 million in 2025.
- Its last three reported values are -$483.4 million in Q2 2025, $4.7 million for Q1 2025, and -$40.0 million during Q2 2024.